Japan’s M’s Science To Test Herpes Virus For Treating Cancers
This article was originally published in PharmAsia News
Executive Summary
M's Science, a Japanese biotechnology startup, expects to begin U.S. clinical trials by the end of the year on its cancer treatment. The company is relying on a naturally occurring herpes simplex virus to target specific cancer cells in people who already have been infected with the virus. M's Science is testing its treatment on head and neck cancers and expects to begin Phase II trials in 2010. Positive results there could lead the firm to expand the treatment's scope to other cancers. (Click here for more - a subscription may be required